摘要
[目的]探讨冠心病活血化瘀治疗后行经皮冠状动脉介入治疗（PCI）的安全性。[方法]将53例冠心病血瘀证患者分为观察组（25例）和对照组（28例），两组均使用阿司匹林、氯吡格雷或噻氯吡定治疗；观察组加用香丹注射液静脉滴注．20～30mL／d，使用3d以上。其他综合治疗如调脂、控制血压、控制血糖等基础治疗不受本研究影响。比较两组术前血清纤维蛋白原（PFIB）、凝血酶原时间（tPT）、部分活化凝血酶原时间（tAPTT）和国际标准化比率（INR）；观察两组心绞痛临床疗效和术后发生出血情况、出血部位和出血量等指标。[结果]与对照组比较，观察组PCI术前，INR、tPT和tAPTT等血清凝血指标显著高于对照组（P〈0．01）；观察组的心绞痛疗效优于对照组（P〈0．05）；两组总出血病例数相似，差异无显著性（P〉0．05）。[结论]冠心病活血化瘀治疗后行经皮冠状动脉介入治疗（PCI）是安全的。
[ Objective] To investigate the effect of preoperative application of blood-activating and stasis-removing herbal medicine on the safety of percutaneous coronary intervention （PCI）. [ Methods] Fifty-three coronary heart disease patients with blood stasis were randomized into groups A （n = 25 ） and B （n = 28）. The two groups were given asprine, clopidogrel （or ticlopidine ） and routine treatment such as decreasing blood lipid, blood pressure and glucose if necessary. Group A was additiondly treated with Xiangdan Injection, 20 - 30 mL/d, for over three days. Preoperative serum fibrinogen （FIB） level, prothrombin time （FF）, activated partial thromboplastin time （AFTT） and international normalization ratio （INR） were compared in the two groups. The therapeutic effect in the two groups as well as postoperative hemorrhage （including amount of bleeding and bleeding regions） was also observed in the two groups. [Results] INR, PT and APTT were higher in group A than those in group B （ P 〈 0.01） ; angina pectoris was much relieved in group A compared to group B （ P 〈 0.05） ; the number of patients with bleeding was similar in the two group, the difference being insignificant （ P 〉 0.05 ）. [ Conclusion ] It is safe to apply blood-activating and stasisremoving herbal medicine before PCI for coronary heart disease.
出处
《广州中医药大学学报》
CAS
2006年第5期375-378,共4页
Journal of Guangzhou University of Traditional Chinese Medicine
关键词
冠状动脉疾病/中西医结合疗法
经皮冠状动脉介入
香丹注射液/治疗应用
活血化瘀
CORONARY DISEASE/TCM-WM therapy
PERCUTANEOUS CORONARY INTERVENTION
XIANGDAN INJECTION/therapeutic use
ACTIVATING BI_f）OD AND REMOVING STASIS
